CClinicalTrials.gg
CompletedNCT03210571Updated Oct 28, 2021

Clinical Investigation of the eyeWatch Glaucoma Drainage Device

An interventional study of eyeWatch system in Open Angle Glaucoma, sponsored by Rheon Medical SA. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Rheon Medical SA · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to test a new medical device, called the eyeWatch, used in filtering surgery for the treatment of glaucoma. This medical device has the following property: it allows better control of intraocular pressure in the initial postoperative phase by adjusting aqueous flow going through the device. The target criteria for the study are defined as: keeping intraocular pressure in target range; reducing the number of anti-glaucoma drugs; evaluating the number and type of postoperative complications. So far, this device has been already tested on 20 patients in Switzerland.

02

Conditions studied

  • Open Angle Glaucoma
03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's enrollment of 27 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Rheon Medical SA is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient must be 18 years of age or older.
  • Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory POAG or PEXG after previous failed filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma.
  • Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study.
  • Patient condition is indicated for primary and secondary filtration surgery.
  • Presence of elevated intraocular pressure defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery.
  • Optic neuropathy is exclusively attributed to glaucoma.
  • Patient agreed to sign the written inform consent prior to entering into the investigation.
  • Patient is able and willing to complete post-operative follow-up requirements.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of neovascular glaucoma, congenital glaucoma.
  • History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery.
  • Proliferative or severe non-proliferative retinopathy in either eye.
  • Congenital anomaly of the anterior chamber angle in the study eye.
  • Optic neuropathy other than glaucoma in the study eye.
  • Patient with retinal vein occlusion in the study eye.
  • Patient with retinal artery occlusion in the study eye.
  • Patient with corneal opacifications, endotheliopathy, or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye.
  • Patient with a history of severe eye trauma in the study eye.
  • Patient with ocular malformations such as microphthalmia in the study eye.
  • Patient with concurrent inflammatory/infective eye disorder in the study eye.
  • Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants.
  • Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation.
  • Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    eyeWatch device

    Device: eyeWatch system

Interventions

  • DeviceeyeWatch system

    The eyeWatch device is composed of an AGDD, a control unit and a draining plate

    Also known as: Adjustable glaucoma drainage device (AGDD)

06

What researchers measure

Primary outcomes

  1. Number and type of serious adverse device events

    Demonstration of safety. The number and type of serious adverse device event per patient will be measured. Results of biomicroscopy, gonioscopy, pachymetry visual field and endothelial count will be compared to baseline.

    Time frame: Follow-up: day 1, Week 1, week 2, month 1, month 2, month 3, month 6, month 12 compared to baseline

  2. Effectiveness in reducing the intraocular pressure

    Demonstration of the performance. The intraocular pressure (IOP in mmHg) will be measured at different time points to show the effective reduction compared to baseline. IOP reduced by ≥ 20% or IOP \< 21 mmHg, and no IOP \< 5 mmHg on two consecutive visits after 1 month (included)

    Time frame: Follow-up: day 1, Week 1, week 2, month 1, month 2, month 3, month 6, month 12 compared to baseline

07

Study locations

1 site
  • St. Thomas' Hospital
    London, SE1 7EH, United Kingdom
08

References and documents

Publications

  • Villamarin A, Roy S, Bigler S, Stergiopulos N. A new adjustable glaucoma drainage device. Invest Ophthalmol Vis Sci. 2014 Mar 25;55(3):1848-52. doi: 10.1167/iovs.13-12626. PubMed 24557347 ↗

Individual participant data

Plan to share: No — There is no plan

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03210571
Lead sponsor
Rheon Medical SA
Responsible party
Sponsor
First posted
Jul 7, 2017
Start date
May 1, 2018
Primary completion
Oct 27, 2020
Completion
Oct 27, 2020
Last update
Oct 28, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion